回盛生物：目前海外业务构成主要以原料药出口为主，制剂出海业务处于探索期

Group 1 - The company is actively expanding its overseas market presence, with positive sales growth in its international business [2] - The primary component of the overseas business is the export of active pharmaceutical ingredients (APIs), while the formulation export business is still in the exploratory phase [2]